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Abstract TopBP1 protein displays structural as well as
functional similarities to BRCA1 and is involved in DNA
replication, DNA damage checkpoint response and tran-
scriptional regulation. Aberrant expression of TopBP1 may
lead to genomic instability and can have pathological
consequences. In this study we aimed to investigate
expression of TopBP1 gene at mRNA and protein level in
hereditary breast cancer. Real-time quantitative PCR was
performed in 127 breast cancer samples. Expression of
TopBP1 mRNA in lobular carcinoma was signiﬁcantly
lower compared with ductal carcinoma (p\0.05). The
level of TopBP1 mRNA appeared to be lower in poorly
differentiated (III grade) hereditary breast cancer in com-
parison with moderately (II grade) and well-differentiated
cancer (I grade) (p\0.05 and p\0.001 respectively). We
analyzed TopBP1 protein expression using immunohisto-
chemistry and Western blot techniques. Expression of
TopBP1 protein was found to be signiﬁcantly increased in
poorly differentiated breast cancer (III grade) (p\0.05).
The percentage of samples with cytoplasmic apart from
nuclear staining increased with increasing histological
grade. There was no signiﬁcant association between level
and intracellular localization of TopBP1 protein in hered-
itary breast cancer and other clinicopathological parame-
ters such as estrogen and progesterone receptors status,
appearance of metastasis in the axillary lymph nodes and
type of cancer. Our data suggest that decreased level of
TopBP1 mRNA and increased level of TopBP1 protein
might be associated with progression of hereditary breast
cancer.
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Introduction
TopBP1 protein (topoisomerase IIb binding protein 1) was
identiﬁed as an interacting partner for topoisomerase IIb [1,
2]. TopBP1 possesses eight BRCA1 (breast cancer gene 1)
carboxyl-terminal (BRCT) domains which were for the ﬁrst
time described for BRCA1 protein and are commonly found
inproteinsinvolvedinregulationofthecellcyclecheckpoint
and the response of the cell to DNA damage [1, 3–5]. The
C-terminal region of TopBP1 containing two BRCTs shows
considerablesimilaritytothecorrespondingpartofBRCA1.
Beside the sequence homology, TopBP1 also displays
functional similarities to BRCA1 [6, 7]. Both proteins are
strongly induced during S phase. Following ionizing radia-
tion, TopBP1 is recruited to DNA breaks and colocalizes
with NBS1 (Nijmegen breakage syndrome protein 1),
BRCA1, and 53BP1 (p53 binding protein 1) in nuclear foci
[7–9]. TopBP1 interacts with several other proteins,
including human papilliomavirus type 16 (HPV16) tran-
scription/replication factor E2, DNA polymerase e, check-
point protein hRad9, and transcription factor E2F1 [8, 10–
15].Thus,TopBP1seemstobeinvolvedinDNAreplication,
DNA damage checkpoint response and transcriptional reg-
ulation [3, 9, 13, 16–19]. TopBP1 protein is essential for
maintenance of chromosomal integrity and cell prolifera-
tion. This protein appeared to be involved in DNA damage
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cation and regulation of transcription [20–22]. TopBP1
knockout mouse exhibits early embryonic lethality at the
peri-implantation stage and TopBP1 deﬁciency induces
cellular senescence in primary cells [20, 22].
Genomic stability in eukaryotic cells is maintained by
checkpoint mechanisms which coordinate cell cycle pro-
gression and other processes including transcription,
apoptosis and DNA repair [3]. Some signals of DNA
damage can lead to cell cycle arrest to prevent transfer of
damaged genetic information to the daughter cells.
Checkpoint responses are considered to be a major mech-
anism to reduce both initiation and progression of cancer,
which can be caused by incomplete DNA repair, resulting
in genetic alterations of tumor suppressor genes and pro-
tooncogenes [7]. TopBP1 appears to be directly involved in
controlling replication initiation. In this regard, its role in
repressing E2F1-mediated apoptosis at the G1/S transition
would be crucial to ensure suppression of apoptosis before
initiation of DNA replication. Like other proteins that are
directly involved in DNA replication, TopBP1 is induced
by E2F1 during G1/S transition. Therefore, TopBP1 acts as
a critical cooperator to enforce the execution of S phase [3,
14, 17]. Both, TopBP1 and BRCA1 speciﬁcally regulate
the G2/M checkpoint partially compensating each function
[7]. At G2/M checkpoint, TopBP1 binds and activates ATR
(ATM and Rad3-related protein) in an ATRIP (ATR
interacting protein)-dependent manner, leading to recruit-
ment and phosphorylation of BRCA1 and subsequent
activation of Chk1 (checkpoint kinase 1) and other ATR
effectors [23, 24]. Activation of Chk1 can lead to cell cycle
arrest and damage repair [7, 14].
Aberrant expression of TopBP1 may be involved in the
deregulation of processes controlled by this protein and can
have pathological consequences. Therefore, the current
study was aimed at investigating expression of TopBP1
gene at mRNA and protein level in hereditary breast
cancers.
Materials and methods
Specimen collection
The studied material was obtained from Polish Mother’s
Memorial Hospital, Research Institute, Lodz, Poland and
comprised of 127 of formalin-ﬁxed parafﬁn embedded
(FFPE) sections of hereditary breast cancers (patients age
range 28–69 years) and 24 normal breast tissues (patients
age range 35–59 years). Apart from FFPE for 50 of 127
breast cancer patients fresh frozen (-80 C) breast tissues
were also obtained. Blood samples were obtained for each
patient. Normal tissues were obtained from women
undergoing radical mastectomy and after resection were
immediately frozen at -80 C. Cancerous and normal
tissues belong to different persons.
Criteria for classifying the samples as hereditary breast
cancers were as follows (1) at least one ﬁrst-degree relative
with breast cancer, regardless of age (n = 92), (2) breast
cancer diagnosed below 40 years of age (n = 35). We
analyzed three BRCA1 mutations (C61G, 4153delA,
5382insC) in DNA of studied breast cancer patients (see
details in Method section). BRCA1 mutations were
detected in 72 of 127 of studied patients. None of the
patients received neoadjuvant endocrine therapy, chemo-
therapy or radiotherapy. A structured questionnaire was
used to collect detailed information on age, age of men-
arche and/or menopause, weight, and family history of
cancer. The pathological evaluation report was obtained for
each patient (Table 1).
Table 1 Characteristics of patient and tumor samples
Characteristics Patients
N %
Normal breast tissue 24
Age range 35–59
Mean ± SD 48.5 ± 10.5
Breast cancer 127
Age of diagnosis
Range 28–69
Mean ± SD 54.3 ± 11.5
Type of cancer
Ductal carcinoma 99 78
Lobular carcinoma 28 22
Tumor grade according to Bloom–Richardson system
I1 4 1 1
II 76 60
III 37 29
Lymph node metastasis
No 72 56
Yes 55 44
Menopausal status
Premenopausal 73 57
Postmenopausal 54 43
ER status
Negative 61 48
Positive 66 52
PR status
Negative 68 33
Positive 59 67
ER estrogen receptor, PR progesterone receptor
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123Analysis of BRCA1 mutations
Mutations of BRCA1 and BRCA2 genes confer a high
lifetime risk for both breast and ovarian cancer. Many
different BRCA1 and BRCA2 mutations have been descri-
bed in families with early-onset breast and ovarian cancer
[25–28]. In Poland three mutations (C61G, 4163delA and
5382insC) in BRCA1 gene account for 86 % of all BRCA1
and BRCA2 mutations [29, 30]. Mutations in BRCA2 are
relatively rare in Poland and no founder BRCA2 mutations
have been identiﬁed [29, 30]. Therefore, we analyzed
presence of C61G, 4163delA and 5382insC in studied
patients with breast cancer.
Genomic DNA was prepared from peripheral blood by
using the commercial GenElute Blood Genomic DNA Kit
(Sigma Aldrich, Germany) according to the manufacturer’s
instruction. The allele speciﬁc oligonucleotides polymerase
chain reaction (ASO-PCR) was used to determine the
studied mutations of BRCA1 gene. PCR assays were per-
formed in a total reaction volume of 25 ll containing 50 ng
of genomic DNA, 1U Taq DNA polymerase (Sigma
Aldrich, Germany), 19 reaction buffer (10 mM Trizma
HCl, pH 8.3; 50 mM KCl; 1.5 mM MgCl2; 0.001 % (w/v)
gelatin), 200 lM of each dNTP, 0.25 lM of each primer.
PCR ampliﬁcations were conducted in GeneAmp PCR
System 9700 (Perkin-Elmer, USA). Thermal cycling con-
ditions were as follows: initial denaturation step at 94 C
for 5 min, 30 cycles at 95 C for 30 s, 30 s at 54 C for
C61[G, 51 C for 4153delA and 60 C for 5382insC,
and 60 s at 72 C. The terminal extension step was per-
formed for 10 min at 72 C. The following allele speciﬁc
oligonucleotides as primers were used: F:50GGTTTCT
CAGATAACTGGGCC30 (wild type variant), F:50GGTT
TCTCAG-ATAACTGGGCG30 (mutated type variant) and
R:50CGTCAAAGAATACCCATCTG30 (common primer)
for C61G mutation; F:50GGCATCTCAGGAACAT-
CACC30 (common primer), R:50CTTGCCCGTTCCTCT
TTCTTC30 (wild type variant) and F:50CTTGCCCGT
TCCTCTTTCTGA30 (mutated type variant) for 4153delA
mutation; F:50TGTTGGTCAGACTGGTGTCG30 (com-
mon primer), F:CATTGACCAC-ATCTCCTCTGAC30
(wild type variant) and F:50CATTGACCACATCTCCT
CTGGA30 (mutated type variant) for 5382insC mutation.
The PCR products (163, 220 and 225 bp) were separated
onto 8 % polyacrylamide gel, stained with ethidium bro-
mide and viewed under UV light.
Total RNA extraction from FFPE breast cancer sections
and fresh frozen normal and cancerous breast tissues
Sections were deparafﬁnized by two rinses in xylene for
10 min at room temperature with shaking, followed by
centrifugations at room temperature for 5 min at
12,0009 g. After deparafﬁnization, we introduced a rehy-
dratation step (rinsing in 100% ethanol, 85, 70 % ethanol,
all prepared with diethylpyrocarbonate (DEPC) treated
dH2O, for 5 min). The tissue was collected by centrifuga-
tion at 12,0009 g for 5 min. After the ﬁnal wash, alcohol
was aspirated. The dried tissue pellets of breast cancer
samples and fresh frozen normal and cancer breast tissues
were resuspended in 500 ll of digestion buffer (10 mM
NaCl; 500 mM Tris–HCl, pH 8.0; 25 mM EDTA; 1 %
SDS) and 1 mg/ml proteinase K was added. Samples were
incubated at 45 C overnight. Prior to RNA puriﬁcation, in
same samples we inactivated proteinase K at 97 C for
10 min. The digested samples were extracted using TRI
Reagent (Sigma Aldrich, USA) according to manufac-
turer’s protocol. RNA was eluted in 20 ll RNase-free
water, quantiﬁed by spectrophotometry at 260 nm and
stored at -20 C. RNA with a 260/280 nm ratio in range
1.8–2.0 was considered high quality. Integrity was evalu-
ated by assessing the 18S and 28S rRNA bands in 1 %
ethidium bromide stained agarose gels.
cDNA synthesis
First strand cDNA was synthesized from each RNA pool
using PCR Kit ver 3.0 (Takara Bio Inc., Japan) according
to the manufacturer’s instruction. Brieﬂy, 1 lg RNA was
combined with 2.5 pmol of oligo dT-adapter primer, 4 ll
of 25 mM MgCl2,2ll1 0 9 RNA PCR buffer, 2 llo f
10 mM dNTP mixture, 20 units of RNase inhibitor, 5 units
of AMV reverse transcriptase XL, and RNase-free water to
total volume of 20 ll. The reaction took place at 42 C for
30 min, followed by 95 C for 5 min and 5 C for 5 min in
a GeneAmp PCR System 9700 (Perkin-Elmer Co, USA).
cDNA was stored at -20 C.
Real-time quantitative PCR
The real-time PCR was performed in Mastercycler ep
Realplex 4S (Eppendorf, Germany). Primers and TaqMan
probes for TopBP1 and GAPDH control reference gene
were designed and synthesized according to TaqMan
Gene Expression Assay (assay Hs00199775_m1 and
Hs00266705_g1, respectively) (Applied Biosystems,
USA). PCR reactions were carried out in a total volume of
10 ll of universal master mix (Applied Biosystems, USA)
and 1 ll cDNA. The reactions were performed in dupli-
cate. A positive result was deﬁned by a threshold cycle (Ct)
value lower than 40 (the Ct value is determined by the
number of cycles needed to exceed the background signal).
Ct value of all positive results were lower than 30. Abun-
dance of TopBP1 mRNA in samples was quantiﬁed by the
DCt method. DCt (CtTopBP1 - CtGAPDH) values were
recalculated into relative copy number values (number of
Mol Biol Rep (2012) 39:7795–7804 7797
123copies of TopBP1 mRNA per 1,000 copies of GAPDH
mRNA).
Sequencing of PCR products
We ampliﬁed fragment of TopBP1 cDNA by PCR and
puriﬁed products using QIAquick puriﬁcation columns
(Qiagen, USA). Both strands were sequenced using a
BigDye Terminator Cycle Sequencing Kit ver. 1.1
(Applied Biosystems, USA) according to the manufac-
turer’s recommendations. Reactions were analysed on an
ABI Prism 377 DNA Sequencer (Applied Biosystems,
USA).
Immunohistochemistry
2 lm tissue sections were deparafﬁnized and rehydrated
through xylene and graded ethanol, respectively. Slides
were rinsed in dH2O, then were subjected to antigen
retrieval in 10 mM citrate buffer, pH 6.0 by microwave
oven heating for 20 min. Endogenous peroxidase activity
was quenched in 0.3 % H2O2 for 30 min, then washed in
dH2O. After blocking in Ready-to-Used Blocking Reagent
(Bethyl, USA), slides were incubated 60 min at room
temperature with rabbit anti-human TopBP1 antibody
(Abcam, ab2402), dilution 1:200. Detection was performed
with Immunohistochemistry Accessory Kit IHC-101
(Bethyl, USA) according to the performed by incubating
the sections in a solution of DAB. Sections were counter-
stained with hematoxylin, dehydrated and coverslipped.
For each antibody and samples a negative control was
processed.
Evaluation of staining
Each case was evaluated in terms of staining intensity as
positive and negative cells. The immunoreactive score
(IRS) of the TopBP1 was estimated by multiplying the
score for staining intensity (0—negative, 1—weak, 2—
moderate and 3—strong staining) and score for the per-
centage of positively stained cells (0 = 0% ;1=\5% ;
2 = 5–35 %; 3 =[35–70 % and 4 =[70 %). An IRS
score of 6 or higher was considered to be a strong reac-
tivity, 4–5 moderate, 2–3 weak and 0–1 negative. The
immunoreactive score results were estimated by two
pathologists.
Western blot analysis
Cytoplasmic and nuclear fractions were separated from 50
cancerous and 24 normal fresh frozen breast tissue samples
by differential centrifugation of tissue homogenate in iso-
tonic sucrose in the presence of the serine protease
inhibitor PMSF and 10 mM sodium molybdate. Nuclei
were ﬁnally puriﬁed by centrifugation through 2.2 M
sucrose. Protein concentration in homogenates and cellular
fractions was evaluated according to Lowry protocol using
bovine serum albumin (BSA) as standard. Proteins of
homogenate as well as cytoplasmic and nuclear fractions
(50 lg) were resolved on 8 % SDS-PAGE and electro-
transferred onto Immobilon-P membrane (Millipore, USA).
The loading and efﬁciency of transfer were veriﬁed by
Ponceau S staining of membranes. After blocking in 0.5 %
casein the membrane was incubated with speciﬁc primary
anti-TopBP1 antibody diluted (1:5,000) in TBS with 0.5 %
casein at 4 C for 12 h. Commercial polyclonal antibody
speciﬁc for the portion of human TopBP1 encoded within
exon 28 was used (Abcam, UK). Following extensive
washing with TBST buffer (Tris-buffered saline with
Tween 20) the membrane was incubated with mouse anti-
rabbit IgG-HRP antibody (Santa Cruz, USA). The speci-
ﬁcity of antigen–antibody interaction was visualized with
4-chloro-1-naphthol and hydrogen peroxide as substrate for
horseradish peroxidase (HRP). The intensities of the visu-
alized signals were analyzed densitometrically.
Statistical analysis
Statistical analysis was performed using the STATISTICA
version 9.0 (SatatSoft, Poland). Analysis of differences
between TopBP1 mRNA and clinical parameters was car-
ried out using the Mann–Whitney test and Kruskal–Wallis
test with post hoc multiple comparisons. Relationships
between TopBP1 protein expression and intracellular
localization and clinicopathological factors were examined
with Chi
2 test. Analysis of the relationship between mRNA
and protein level was performed using Spearman rank test.
p value of p\0.05 was considered statistically signiﬁcant.
Results
The expression of TopBP1 gene at the mRNA level in nor-
mal breast tissue and hereditary breast cancer was estimated
by real-time quantitative PCR analysis with GAPDH gene
applied as a reference. Sequencing of PCR products con-
ﬁrmed that ampliﬁcation product correspond with full-
length sequence of TopBP1 and there were no other iso-
forms. In case of 50 cancer samples TopBP1 mRNA
expression was analyzed both in FFPE sections and fresh
breast tissues. Since there was no differences between
mRNA expression in FFPE samples and fresh tissues only
results from FFPE sections are presented on diagrams and
table. The comparison of TopBP1 mRNA level with dif-
ferent clinicopathological parameters of tumors is shown in
Table 2, where the average of TopBP1 mRNA copies per
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1231,000 copies of GAPDH mRNA represent the mean level of
TopBP1 mRNA, and are used for statistical analysis. Top-
BP1 mRNA expression was observed in all of 24 (100 %)
normal breast tissue samples and in 97 of 127 (76.4 %)
breast cancer samples. Thus, positive expression of TopBP1
mRNA in normal tissue was more frequently observed
compare to breast cancer samples (p\0.05). Level of
TopBP1 mRNA was signiﬁcantly higher in normal breast
tissues than in breast cancer specimens (p\0.01; Fig. 1a).
Expression of TopBP1 mRNA was found to be signiﬁcantly
decreased in the lobular carcinoma compared to the ductal
carcinoma (p\0.05; Fig. 1b). Fifteen of 28 (53.6 %) lob-
ular carcinoma demonstrated detectable mRNA for TopBP1
gene, while the expression of TopBP1 mRNA was observed
in 76 of 99 (78.3 %) ductal carcinoma. Expression of Top-
BP1 gene at the mRNA level was observed in 62.0 % (23/
37) of poorly differentiated breast cancer (grade III),
whereas nearly 80 % of tumors in I and II grade demon-
strated detectable TopBP1 mRNA (78.6 % (11/14) and
78.9 % (60/76), respectively). Signiﬁcantly lower TopBP1
mRNA level in the poorly differentiated (grade III) familial
breast cancer compared with moderately (grade II, p\
0.01) and well-differentiated cancer (grade I, p\0.001)
was noted (Fig. 1c). There was no statistically signiﬁcant
difference in the context to clinicopathological parameters
such as estrogen and progesterone receptor status and
appearance of metastasis in the axillary lymph nodes.
The expression level of TopBP1 protein was determined
in 127 breast carcinoma samples using immunohistochem-
ical technique. The results concerning correlation between
TopBP1 expression and clinicopathological parameters of
breastcancersareshowninFig. 2andTable 3.TopBP1was
expressed in 121 of 127 (95.3 %) breast cancers. In 80/121
(66.1 %) there were heterogenous immunoreactivity with
areas of nuclear and cytoplasmic staining (4cases ingrade I,
52 cases in grade II and 24 cases in grade III). Of the 121
cases,51(40.1 %)hadaweakexpressionofTopBP1protein
(IRS score 2–3), 61 (48.0 %) a moderate expression (IRS
score4–5)and9(7.1 %)astrongexpression(IRSscoreC6).
Table 2 Expression of TopBP1 mRNA in cancerous and normal
breast tissues
Clinicopathological
features (N)
Quantitative RT-PCR
(copies of TopBP1 mRNA
per 1000 copies
GAPDH mRNA)
p
Normal breast tissue (24) 587.2 ± 108.4
Breast cancer (127) 243.0 ± 27.9 0.002
Type of cancer
Ductal carcinoma (99) 266.9 ± 31.2
Lobular carcinoma (28) 94.6 ± 34.1 0.03
Tumor grade
I (14) 465.4 ± 121.6
II (76) 245.1 ± 32.7
III (37) 118.9 ± 34.4 0.003
Lymph node status
No (72) 282.9 ± 40.8
Yes (55) 196.8 ± 35.6 0.12
ER status
Negative (61) 218.0 ± 37.9
Positive (66) 269.8 ± 40.6 0.35
PR status
Negative (68) 204.6 ± 38.3
Positive (59) 276.7 ± 39.4 0.71
ER estrogen receptor, PR progesterone receptor
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Fig. 1 Expression of TopBP1 mRNA measured by real-time PCR.
a in normal breast tissue and hereditary breast cancer, b in relation to
type of cancer and c tumor grade. Graphs represent mean ± SEM
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123Pathological grading was associated with TopBP1 protein
expression.AlltumorsamplesclassiﬁedasgradeIandgrade
II showed TopBP1 protein expression. In grade I, 12 cases
had a weak and 2 a moderate expression and 0 cases strong
TopBP1protein expression. Six of37 samplescharacterized
as grade III had a negative TopBP1 protein expression,
whereas4hadaweak,22amoderate,and5astrongTopBP1
protein expression. There was no expression difference
between type of tumor, lymph node status, and steroid
hormone receptors status (Fig. 2; Table 3).
Expression of TopBP1 protein was also examined using
Western blot, in both normal breast tissue and carcinoma
specimens in 24 and 50 cases, respectively. The results
concerning TopBP1 expression in homogenates and its
cellular localization are shown in Fig. 3c. Among 50 ana-
lyzed tumors, 4 were classiﬁed as grade I, 30 as grade II and
16 as grade III. The mean level of TopBP1 in homogenates
was higher in cancer samples compared to normal cells
(p\0.05). Moreover, we observed higher TopBP1 protein
level in the poorly differentiated breast cancers compared to
moderately and well-differentiated cancers (Fig. 3a, b).
These results are consisted with the results obtained with
immunohistochemistry method (Fig. 2).
TopBP1 protein was found in the nuclear fraction of all
normal breasttissue samples. LowlevelofTopBP1wasalso
detected in cytoplasmic fraction of seven normal tissue
specimens.TopBP1proteinwasfoundinallnuclear andone
cytoplasmic fraction of analyzed breast cancer in grade I.
Pattern of TopBP1 protein expression in well-differentiated
breast cancer was similar to normal breast tissue samples. In
10 of 30 moderate differentiated breast cancers expression
of TopBP1 was observed only in the nuclear fraction. In the
remaining 20 tumor samples in grade II, TopBP1 protein
was also detected in cytoplasmic fraction. However, level of
this protein was lower in cytoplasmic fraction than nuclear
fraction. In the case of four poorly differentiated breast
cancer, TopBP1 protein was in the nuclear fraction and was
absentinthecytoplasmicfraction. In6of16breastcancerin
grade III, TopBP1 protein was reveals in both the nuclear
and cytoplasmic fractions. However, the level of TopBP1
protein in two of these samples was higher in cytoplasmic
fraction than in the nuclear fraction.
The results of TopBP1 protein expression showing
higher TopBP1 level in cancer samples compared to nor-
mal tissues are in contrast to the results concerning mRNA
level of TopBP1. In most cases of tumors we observed
lower level of mRNA level than in normal tissue. More-
over, in most cases of tumors we found an inverse corre-
lation between protein and mRNA level (Spearman’s rank
analysis, R =- 0.61, p[0.05).
Discussion
Breastcancer isthecommonestmalignancyinwomenandit
is estimated that a million women worldwide will develop
breast cancer each year [31]. About 5–10 % of the cases are
considered familial [6]. A number of high penetrance breast
cancer susceptibility genes have been identiﬁed and include
BRCA1 andBRCA2.Thesegenes conferahighriskofbreast
and ovarian carcinoma. About 40–50 % of familial breast
cancer can currently be explained by mutations in BRCA1
andBRCA2 genes.Of theremainingcasesnomorethan5 %
a
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Fig. 2 Immunohistochemical analysis of TopBP1 protein expression.
a representative TopBP1 immunostaining results for formalin-ﬁxed
parafﬁn-embedded tissue of carcinoma ductale (original magniﬁca-
tion, 9200), b expression of TopBP1 protein in relation to type of
cancer and c tumor grade
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123are caused by defects in other studied genes, such as p53,
PTEN, ATM and Chk2 [6, 32, 33]. It is not known how many
more genes that confer a small risk are yet to be identiﬁed or
howthesegenes cometogetherorinteract with each otheror
with environmental factors to increase to breast cancer risk
[31]. Most of the known cancer susceptibility genes encode
proteins involved in the monitoring of genome integrity.
Therefore, Karppinen et al. [6] suggested, that TopBP1
coding for protein displaying structural and functional
similarities with BRCA1 can be a plausible susceptibility
gene for hereditary breast and ovarian cancer.
In this study we examined the relationship between
expression of TopBP1 gene at the mRNA and protein level
and clinicopathological parameters of hereditary breast
cancers. In the literature there is no data concerning
expression of TopBP1 at mRNA level in normal and can-
cerous tissues and only a few studies have examined the
expression of TopBP1 protein in female breast cancer
[34–37].
Our results obtained by immunohistochemical and
Western blot analyses showed higher level of TopBP1
protein in breast cancer samples compared with normal
breast tissues. Moreover, patients with overexpression of
TopBP1 tend to have higher grades of breast cancer than
those without overexpression of TopBP1. These results are
consistent with results of Liu et al. [37] who have also
showed higher expression of TopBP1 in breast cancers than
normal tissues and found that patients with overexpression
of TopBP1 in the tumors have signiﬁcantly shorter overall
survival time and shorter progression free survival time
than those without overexpression of TopBP1. Therefore,
TopBP1 may be an important prognostic marker for
aggressive subgroups of breast cancer [37]. Since TopBP1
is involved in regulation of promoter binding activity of
p53 during normal growth, the authors suggest that, its
abnormally high level may potentially inactivate p53 and
contribute to an aggressive behavior of breast tumors [37].
Going and coworkers [34] who analyzed the TopBP1
expression by immunohistochemistry in normal and can-
cerous breast tissues reported the signiﬁcant changes in
TopBP1 localization. In normal breast tissue, TopBP1
staining was almost entirely nuclear in location, although
in rare cells some cytoplasmic staining was occasionally
detected [34]. The nuclear localization is consistent with
the function of TopBP1 which is involved in DNA damage
response and initiation of DNA replication [4, 15]. How-
ever, the pattern of TopBP1 staining in human breast tis-
sues changed from predominantly nuclear in normal
epithelium, to nuclear and cytoplasmic or purely cyto-
plasmic in most of cancers [34]. Expression of TopBP1
was also reported in feline and canine mammary neoplasia
[35, 36]. TopBP1 staining was predominantly nuclear, but
in some tumors there was additional cytoplasmic staining
[35, 36]. Expression of TopBP1 protein in feline and
canine mammary neoplasia was positively correlated with
histological grade and additionally to nuclear, cytoplasmic
Table 3 Correlation between TopBP1 protein expression and clinicopathological ﬁndings
Clinicopathological features (N) IRS No (%) p
Negative 0–1 Weak 2–3 Moderate 4–5 Strong C6
Hereditary breast cancer (127) 6 (4.7) 51 (40.1) 61 (48.0) 9 (7.1)
Type of cancer
Ductal carcinoma (99) 6 (6.1) 36 (36.4) 49 (49.5) 8 (8.0) 0.25
Lobular carcinoma (28) 0 (0) 15 (53.6) 12 (42.8) 1 (3.6)
Tumor grade
I (14) 0 (0) 12 (85.7) 2 (14.3) 0 (0) \0.0001
II (76) 0 (0) 53 (69.7) 20 (26.3) 3 (3.9)
III (37) 6 (16.2) 4 (10.8) 22 (59.4) 5 (13.5)
Lymph node status
No (72) 4 (5.6) 32 (44.4) 27 (37.5) 4 (5.5) 0.91
Yes (55) 2 (3.6) 30 (54.5) 24 (43.6) 4 (7.3)
ER status
Negative (61) 2 (3.3) 35 (57.4) 30 (49.2) 3 (4.9) 0.81
Positive (66) 4 (6.1) 27 (40.9) 21 (31.8) 5 (7.6)
PR status
Negative (68) 3 (4.4) 34 (50.0) 27 (39.7) 4 (5.9) 0.99
Positive (59) 3 (5.1) 28 (47.4) 24 (40.7) 4 (6.8)
ER estrogen receptor, PR progesterone receptor
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123staining was observed as the degree of malignancy
increased [34–36]. Our results concerning localization of
TopBP1 are consistent with results ascribed as above. We
also found in normal tissue mainly nuclear localization of
TopBP1 whereas in most cancer tissue samples TopBP1
localized also in cytoplasmic compartment. The percentage
of samples with cytoplasmic expression of TopBP1
increased with increasing histological grade. However,
there was no signiﬁcant association between level and
intracellular localization of TopBP1 protein in hereditary
breast cancer and other clinicopathological parameters as
estrogen and progesterone receptors status, appearance
of metastasis in the axillary lymph nodes and type of
cancer.
There are no studies that demonstrated expression of
TopBP1 at mRNA level and its relationship to TopBP1
protein level in normal and cancerous breast tissues. The
results of our present study surprisingly showed lower level
of TopBP1 mRNA in cancer samples compared to normal
tissues. We also found that expression of TopBP1 mRNA
contrary to TopBP1 protein level was inversely correlated
with histological grade of hereditary breast cancers.
Moreover, expression of TopBP1 mRNA was signiﬁcantly
down-regulated in the lobular carcinoma compared to the
ductal carcinoma. However, we did not ﬁnd any correlation
between TopBP1 protein level and type of breast cancer.
At present we do not know the reason of discrepancies
between TopBP1 mRNA and protein level. The lack of
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Fig. 3 Western blot analysis of
TopBP1 protein expression and
localization. a TopBP1 protein
expression in homogenate
samples of normal and cancer
breast tissue (sample no. 15 was
used as a reference sample),
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analysis of the intensity of
TopBP1 bands in normal and
cancer breast samples, and in
relation to tumor grade,
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localization of TopBP1 in
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123compatibility between alteration in mRNA and protein
levels conﬁrms that there is no simple and direct relation
between transcriptom and proteome. Many factors may
inﬂuence on the protein content in the cells. We suggest
that in regulation of TopBP1 mRNA and protein levels a
kind of negative feedback control mechanism may be
involved. Down-regulation of mRNA concurrent with up-
regulation of protein level may occur when a protein half-
life is increased due to stabilization because components
involved in the protein’s normal turnover may be disrupted
or the protein may be stabilized through protein–protein
interactions. There is possibility that in cancer cells Top-
BP1 is more stable and can be accumulated. We do not
know what could make TopBP1 more stable but it can be
associated with TopBP1 mislocalization in cancer cells.
Accumulated TopBP1 may act as a repressor of tran-
scription. Our results showing inverse correlation between
TopBP1 mRNA and protein levels in breast cancers seem
to conﬁrm this hypothesis. Expression of TopBP1 gene is
regulated by E2F1 and Egr-1 [38, 39]. On the other hand
TopBP1 regulates activity of E2F1 and high level of this
protein suppresses E2F1 transcriptional activity without
affecting E2F1 protein levels [8, 14]. Thus, decreased
transcriptional activity of E2F1 by TopBP1 may repress the
expression of E2F1 target genes, including TopBP1.
In summary, the association between TopBP1 mRNA
and protein expression and aggressive behavior of breast
cancer could have a potential therapeutic implication.
However, mechanisms of TopBP1 expression regulation
need to be elucidated.
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